APD 597

Drug Profile

APD 597

Alternative Names: APD597; JNJ-38431055

Latest Information Update: 18 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arena Pharmaceuticals
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action GPR119 protein agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Type 2 diabetes mellitus

Highest Development Phases

  • Suspended Type 2 diabetes mellitus

Most Recent Events

  • 09 Nov 2010 Ortho-McNeil-Janssen Pharmaceuticals announces termination of collaboration with Arena Pharmaceuticals
  • 09 Nov 2010 Safety and pharmacokinetics data from a phase I clinical programme released by Arena Pharmaceuticals
  • 19 Dec 2008 Phase-I clinical trials in Type-2 diabetes mellitus in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top